Actively Recruiting
Evaluating Three First-Line Chemotherapy Approaches for Classical Hodgkin Lymphoma in Adults Aged 18 to 50 in Russia
Led by State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia · Updated on 2024-09-27
300
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating three different first-line chemotherapy approaches for patients with classical Hodgkin Lymphoma HL in Russia, focusing on early favorable, early unfavorable, and advanced stages of the disease. This phase III, non-randomized, open-label, multicenter study aims to assess the effectiveness, safety, and progression-free survival of these treatment strategies in patients aged 18 to 50 years. The treatments vary by disease stage early favorable patients receive ABVD chemotherapy with PET scan-guided decisions for additional chemotherapy or radiotherapy early unfavorable patients receive EACODD-14 chemotherapy, followed by possible de-escalation or additional chemotherapy and radiotherapy based on PET scans advanced stage patients also receive EACODD-14 with treatment adjustments guided by PET scan results and tumor size. High-dose chemotherapy with autologous stem cell transplantation is planned for patients with positive biopsy or PET scans indicating poor response. Participants will undergo regular PET-CT scans to monitor treatment response at specific cycles, along with clinical and laboratory assessments. Researchers will measure complete remission, acute and late toxicity, event-free survival, and disease-free survival over up to 5 years. The study includes safety monitoring and long-term follow-up to evaluate overall survival and treatment outcomes throughout the participation period.
CONDITIONS
Brief Title
First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)
Research Team
V
Vladislav Sarzhevskiy, PhD
N
Nikita Mochkin, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here